About
Treatments for oxidative stress
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Team (21)
Benjamin R
Benjamin R. Yerxa, PhD
Nacuity Pharmaceuticals
team_member
Carol Lakkis
Carol Lakkis, BScOptom, PhD, PGCertOcTher
Nacuity Pharmaceuticals
team_member
Charles Lieser
Charles Lieser, JD, CPA
Nacuity Pharmaceuticals
team_member
Daniel Feller
Daniel Feller
Nacuity Pharmaceuticals
team_member
David Birch
David Birch, PhD
Nacuity Pharmaceuticals
team_member
David Wohlberg
David Wohlberg, Esq.
Nacuity Pharmaceuticals
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
91
By Phase
PHASE1/PHASE2: 3
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05994534Lead Sponsor
PK and PD Study of NPI-001 and Cysteamine Bitartrate
PHASE1/PHASE2Recruiting
12 participants
Started: Oct 29, 2023 · Completed: Jun 21, 2025
NCT05026632Lead Sponsor
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
PHASE1/PHASE2Recruiting
30 participants
Started: Jan 27, 2022 · Completed: Dec 31, 2025
NCT04355689Lead Sponsor
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
PHASE1/PHASE2Active, not recruiting
49 participants
Started: Sep 3, 2020 · Completed: Aug 31, 2025
Locations (1)
Headquarters
Fort Worth, TX, United States
Map
Loading map...